It has begun: Foxconn amassing army of workers for iPhone 18 Pro assembly
appleinsider - Months ahead of the fall launches, and historically right on time, Apple supply chain partner Foxconn has started to hire a small army of assemblers to build the iPhone 18 Pro.Workers at a Foxconn facility - Image source: FoxconnEach summer, the Apple sup…
AI Summary: Agenus has suspended the BATTMAN clinical trial and announced a follow‑on program called ROBBIN after strategic reassessment, a move that has raised questions about transparency and participant communication. The abrupt pivot highlights tensions between rapid corporate decision‑making and the need to maintain patient trust in oncology research.
US court rules abortion pill restrictions 'unlawful'
medicalxpress - A federal court in Virginia has ruled that restrictions imposed by the U.S. drug regulator on the abortion pill mifepristone are "unlawful" and ordered the Trump administration to reconsider them.
AI Summary: A U.S. court ruled recent restrictions on the abortion pill unlawful, reaffirming FDA regulatory standards and restoring broader access. Industry groups filed briefs backing FDA oversight, warning that legal uncertainty would harm patients and research. The ruling calms access for now while legal and policy debates continue.
Live attenuated vaccines alone or in combination with an adenovirus-based vaccine protect mice lacking IFN-γ against pneumonic plague
Emily K. Hendrix, Jian Sha, Paul B. Kilgore, Blake H. Neil, Atul K. Verma, Heidi Spratt, Ashok K. Ch / science - Science Translational Medicine, Volume 18, Issue 859, July 2026.
AI Summary: Preclinical work shows that a live attenuated vaccine, alone or combined with an adenovirus vector, protected mice lacking key interferon‑gamma defenses from pneumonic plague. The strategy delivered surprising protection in immunocompromised models, suggesting a potential path forward for vaccines designed to work even when classical immune pathways are impaired.
Could this enzyme help remove 'zombie' cells from our tissues?
medicalxpress - Our population is aging. The United Nations reports that by 2050, the number of people age 85 and older on our planet is set to triple. But a longer life span isn't the same as a longer health span (the number of years we spend healthy). Salk Institute sc…
AI Summary: Researchers identified an enzyme that selectively targets senescent “zombie” cells, restoring tissue function in preclinical models and hinting at anti‑aging and therapeutic possibilities. The findings generated excitement for potential disease‑modifying strategies, but experts caution that translating enzyme‑based fixes from mice to humans will require careful safety studies and sober expectations.
FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial
Adam D. Cohen / nature - Nature Medicine, Published online: 22 July 2026; doi:10.1038/s41591-026-04522-3In a phase 1 trial, the maximum tolerated dose for an FcRH5-containing bispecific T cell engager was not reached, and there was an encouraging response rate in patients with re…
AI Summary: A phase 1 study of the FcRH5×CD3 bispecific antibody cevostamab reported manageable safety and early signals of activity in relapsed or refractory multiple myeloma. Investigators outlined dosing, adverse events and preliminary responses, setting the stage for larger studies and combination trials as patients and advocates watch for broader access to T‑cell‑engaging therapies.
$10B M&A Deal Pays Off With GSK’s First Lung Cancer Drug Approval
Frank Vinluan / medcitynews - GSK drug Jideytro received FDA approval for treating advanced cases of non-small cell lung cancer driven by ROS1 alterations. This molecule came from Nuvalent, which GSK recently acquired for $10.6 billion. The post $10B M&A Deal Pays Off With GSK’s First…
AI Summary: GSK has won FDA approval for its first lung cancer drug, a gene-targeting therapy that validates the company’s heavy investment and recent M&A strategy. The approval follows pivotal trial evidence of clinical benefit and positions GSK competitively in thoracic oncology, offering a new therapeutic choice for patients with the relevant molecular profile.
D.C. appeals court sides with HHS in 340B drug discount program rebate challenge
fiercehealthcare - The ruling upheld a previous decision that pharma companies cannot impose rebates without HHS Secretary approval.
AI Summary: The D.C. appeals court sided with HHS in a legal challenge over 340B drug discount rebates, affirming federal authority over the program’s rebate models. The ruling preserves HHS policy changes that influence pricing and hospital participation, potentially reshaping pharmacy discounts and provider finances nationwide.
- Appeals court and federal rulings cement HHS 340B authority (3)
- CMS reimbursement shakeup: winners, losers and litigation fallout (3)
- HRSA’s revised 340B rebate pilot and oversight push (3)